Core Viewpoint - The company, Rundu Co., Ltd. (002923.SZ), has received approval from the National Medical Products Administration for the marketing application of Isosorbide Dinitrate, which is indicated for the long-term treatment of coronary heart disease and prevention of angina pectoris [1] Group 1 - The approved drug is suitable for the long-term treatment of coronary heart disease [1] - It is also indicated for the prevention of angina pectoris [1] - The drug can be used in conjunction with digoxin and/or diuretics for the treatment of chronic congestive heart failure [1] Group 2 - The drug is indicated for the treatment of pulmonary hypertension [1] - The approval signifies a potential growth opportunity for the company in the cardiovascular treatment market [1]